HopeStage
Back to all studies
CompletedNCT02593643

Ketamine for Suicidal Thoughts in Depression and Bipolarity

About this title

Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

Read the official source — NCT02593643
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2016
Recruitment status
Completed
Enrollment listed in the registry
9
Sponsor
Sunnybrook Health Sciences Centre
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT02593643
Official title
Show the full official title

A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sunnybrook Health Sciences Centre.

Did this study involve medication?

Yes. The study involved medication, including ketamine and Midazolam.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies